Oncology
Oral SERDs Face the Hard Test: Where Do They Actually Fit?
ASCO 2026 giredestrant updates show why oral SERDs remain promising in ER-positive breast cancer, but also why stage, sequence and resistance biology matter.
ASCO 2026: Are we overtreating cancer?
ASCO 2026: Why oncology is also paying attention to GLP-1 medicines
Regulators Start Writing the Rules for AI-Driven Medicines
AI Pathology Moves From Demo to Workflow
FDA Puts AI Inside the Evidence Machine
AlphaGenome Makes Variant Interpretation Political
AI Diagnosis Has Entered the Access Debate
Oncology Trials Still Do Not Match the Patients They Will Treat
Cancer Pharmacogenomics Exposes an Ancestry Gap in Routine Testing
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.